Live Quote · OTCPKTXHealthcare· Biotechnology

ProtoKinetix, Incorporated

$0.01 0.00%(+$0.00)
TickerSpark Score
38/100
Weak
30
Valuation
20
Profitability
60
Growth
52
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PKTX research report →

52-Week Range14% of range
Low
$0.00
Current
$0.01
High
$0.01
Company Overviewwww.protokinetix.com

About the company

ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia.

CEO
Michael Richard Guzzetta
IPO
2002
Employees
5
HQ
Marietta, OH, US

Price Chart

-36.43% · this period
$0.01$0.01$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$2.04M
P/E
-13.00
P/S
0.00
P/B
8.09
EV/EBITDA
-8.64
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-86.22%
ROIC
-104.22%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-364,000 · 12.29%
EPS
$-0.00 · 90.00%
Op Income
$-311,000
FCF YoY
48.74%
Performance & Tape
52W High
$0.01
52W Low
$0.00
50D MA
$0.01
200D MA
$0.01
Beta
0.75
Avg Volume
33.22K

Get TickerSpark's AI analysis on PKTX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 17, 26Jones Michael Winstonother0
Sep 26, 24SMITH CLARENCE EDWARDbuy2,000,000
Jun 14, 24SMITH CLARENCE EDWARDbuy3,100,000
Jun 13, 24SMITH CLARENCE EDWARDbuy3,400,000
Mar 29, 24SMITH CLARENCE EDWARDbuy2,500,000
Mar 20, 24SMITH CLARENCE EDWARDbuy666,667
Dec 26, 23SMITH CLARENCE EDWARDbuy7,333,334
Oct 26, 23Guzzetta Michael Richardbuy20,000
Aug 29, 23SMITH CLARENCE EDWARDbuy1,500,000
Jun 15, 23SMITH CLARENCE EDWARDbuy2,000,000
Coverage · PKTX

Our PKTX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on PKTX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate PKTX report →
Internal Compare

Similar companies

Peers in the same neighborhood.